ERBB2 and breast cancer: Therefore, this first phase III study, which looked at long-term survival after treatment with biosimilar trastuzumab, found long-term survival similar to the reference trastuzumab in patients with MBC and identified the biosimilar trastuzumab-dkst as similar to the reference trastuzumab in terms of clinical outcomes in patients with HER2+ BC [49].